Currently, 24 million people live with asthma in the United States, with 6.3 million of those being children. There is no question that asthma is having a big impact on the health of our nation and how health care is utilized.
According to the 2012 National Ambulatory Medical Care Survey, there were 10.5 million visits to physician offices by patients with asthma as a primary diagnosis.1
But what if there was a way to reduce the impact of wheezing and asthma and potentially help future generations of children?
That is what the Oral Bacterial Extract (ORBEX) Study aims to do.
The ORBEX Study is a three year study to identify if a daily capsule of Broncho-Vaxom will help prevent or delay young children from developing wheezing or asthma-like symptoms. Broncho-Vaxom has already been used by 43 million children in countries all over the world.
A key contributor to the success of the ORBEX Clinical Study is engagement with physicians and other health care providers, as they are the information gatekeepers for their patients - with 70 percent of U.S. adults receiving information, care or support from a doctor or other health care professional.
Which is why we need your help.
If you have a patient that you believe would meet the following eligibility criteria, please refer them to participate in the ORBEX Clinical Study:
- Child is between the ages of 5 - 17 months;
Must meet at least one of the following criteria; and
- One of the child’s parents has asthma or has been diagnosed with asthma in the past
- Child has been diagnosed with eczema
- Child has at least one parent/legal guardian who has a working cell phone and can communicate with study staff.
Below are resources that you can use in your office to inform your patients of the ORBEX Clinical Study.
If you have further questions about the ORBEX Clinical Trial, please fill out this form and a clinical site coordinator will get back to you.
1 Asthma. (2016, June 13). Retrieved August 22, 2016, from http://www.cdc.gov/nchs/fastats/asthma.htm